Trials / Completed
CompletedNCT02140736
Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology
Role of biOsimilaRs in Therapeutic Management of Anemia Following Chemotherapy in HEmatology and Oncology; A Prospective, Observational, Non-interventional Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,333 (actual)
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of this study is to observe correction of the hemoglobin level in the patients under chemotherapy, treated with epoetin alfa biosimilar and presenting with a solid tumor or a lymphoma or a myeloma.
Detailed description
This is a non-interventional, descriptive, national, multi-site, longitudinal and prospective observational study with adults patients who are suffering from cancer or malignant blood disease and whose chemotherapy treatment has induced symptomatic anemia and being treated with biosimilar of epoetin to correct haemoglobin levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epoetin biosimilar |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2011-08-01
- Completion
- 2011-08-01
- First posted
- 2014-05-16
- Last updated
- 2024-02-28
Locations
172 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02140736. Inclusion in this directory is not an endorsement.